Skip to main content

Table 5 Ibrutinib in clinical trials

From: Novel agents for chronic lymphocytic leukemia

Study agents

Other agents

Disease

Dosage

Clinical trials

No Pts

Response

Reference

Ibrutinib

 

Relapsed

420 mg

Phase I

14

CR:14%

[38]

Refractory

OR:79%

Untreated

420/840 mg

Phase Ib/II

116

CR:10/3/0%

[39]

   

ORR:71/67/50%

 

Ibrutinib

Relapsed/Refractory

  

High risk

     

Ibrutinib

Rituximab

High risk

420 mg

Phase II

40

ORR:85%

[43]

  1. Abbreviations: ORR overall response rate, OR overall response, CR complete remission.